February 4, 2026 Sweden
Insights Accelerated: Enough thinking, time for results – Diamyd Medical’s pivotal path to 2026
In an interview with Ventures Accelerated, Ulf Hannelius, CEO of Diamyd Medical, outlines the company’s transition from long-term strategy to a results-driven phase as its pivotal Phase 3 study advances toward the upcoming interim efficacy readout in March 2026.
Read the article here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.